VanEck Biotech ETF (NASDAQ:BBH) Sees Significant Decline in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 6,883 shares, a decline of 63.1% from the January 15th total of 18,670 shares. Based on an average trading volume of 7,434 shares, the short-interest ratio is presently 0.9 days. Currently, 0.3% of the shares of the company are short sold. Currently, 0.3% of the shares of the company are short sold. Based on an average trading volume of 7,434 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in VanEck Biotech ETF by 40,463.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after buying an additional 492,843 shares during the period. Raymond James Financial Inc. increased its position in VanEck Biotech ETF by 245.9% in the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after purchasing an additional 48,297 shares during the last quarter. Bleakley Financial Group LLC bought a new position in shares of VanEck Biotech ETF in the 2nd quarter valued at about $2,909,000. LPL Financial LLC lifted its stake in shares of VanEck Biotech ETF by 63.5% in the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock valued at $6,021,000 after purchasing an additional 12,351 shares during the last quarter. Finally, Paragon Private Wealth Management LLC boosted its stake in VanEck Biotech ETF by 223.5% during the third quarter. Paragon Private Wealth Management LLC now owns 13,394 shares of the company’s stock worth $2,219,000 after buying an additional 9,254 shares during the period. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Up 0.7%

Shares of VanEck Biotech ETF stock opened at $195.72 on Thursday. The stock’s fifty day moving average is $193.61 and its 200 day moving average is $180.62. VanEck Biotech ETF has a one year low of $135.34 and a one year high of $202.91.

VanEck Biotech ETF Dividend Announcement

The business also recently disclosed an annual dividend, which was paid on Friday, December 26th. Stockholders of record on Monday, December 22nd were given a dividend of $0.9565 per share. This represents a dividend yield of 50.0%. The ex-dividend date of this dividend was Monday, December 22nd.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.